Pharmacokinetics of tramadol in a diverse healthy Chinese population

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 5, 2012, Pages 599-603

  Xia, D Y ^a   Wang, Y H ^b   Guo, T ^a   Li, X L ^c   Su, X Y ^c   Zhao, L S ^b,c  

^a SHENYANG NORTHERN HOSPITAL   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c Northeast Pharmaceutical (Shenyang) Science and Technology Development Co Ltd   (China)

Author keywords

Chinese Han; Chinese Hui; Chinese Korean; Chinese Mongolian; Chinese Uygur; gender; pharmacokinetics; tramadol

Indexed keywords

TRAMADOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DIAPHORESIS; DISTRIBUTION VOLUME; DRUG CLEARANCE; ETHNIC DIFFERENCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VERTIGO; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; ETHNIC GROUPS; FEMALE; HUMANS; MALE; SEX FACTORS; TRAMADOL; YOUNG ADULT;

EID: 84865865006     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01345.x     Document Type: Article

References (21)

1. Schnitzer TJ, Kamin M, Olson WH,. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum, 1999; 42: 1370-1377. (Pubitemid 30265594)
2. Grond S, Zech D, Lynch J, et al. Tramadol-a weak opioid for relief of cancer pain. Pain Clinic, 1992; 5: 241-247. (Pubitemid 23032817)
3. Tuncer S, Pirbudak L, Balat O, et al. Adding ketoprofen to intravenous patient-controlled analgesia with tramadol after major gynecological cancer surgery: a double-blinded, randomized, placebo-controlled clinical trial. Eur J Gynaecol Oncol, 2003; 24: 181-184. (Pubitemid 36389367)
4. Close BR,. Tramadol: does it have a role in emergency medicine? Emerg Med Australas, 2005; 17: 73-83. (Pubitemid 40223128)
5. Raffa RB, Nayak RK, Liao S,. The mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Reviews in Contemporary Pharmacotherapy, 1995; 6: 485-497.
6. Garcia-Quetglas E, Azanza JR, Cardenas E, et al. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. Biopharm Drug Dispos, 2007; 28: 19-33. (Pubitemid 46165161)
7. Desmeules JA, Piguet V, Collart L, et al. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Pharmacol, 1996; 41: 7-12. (Pubitemid 26009905)
8. Leppert W, Luczak J,. The role of tramadol in cancer pain treatment-a review. Support Care Cancer, 2005; 13: 5-17. (Pubitemid 40193060)
9. Grond S, Sablotzki A,. Clinical pharmacology of tramadol. Clin Pharmacokinet, 2004; 43: 879-923. (Pubitemid 39447033)
10. Kukanich B, Papich MG,. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. J Vet Pharmacol Ther, 2004; 27: 239-246. (Pubitemid 39141609)
11. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos, 2001; 29: 1146-1155. (Pubitemid 32660534)
12. Wu WN, McKown LA, Liao S,. Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica, 2002; 32: 411-425. (Pubitemid 34620945)
13. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet, 1997; 60: 284-295. (Pubitemid 27058401)
14. Bolton S,. Pharmaceutical statistics: practical and clinical applications, 4th edn. New York, NY: Marcel Dekker, 2004.
15. Boeckman AJ, Sheiner LB, Beal SL,. NONMEM users guide-part V. San Francisco, CA: University of California, 1994.
16. Food and Drug Administration. Guidance on ethnic factors in the acceptability of foreign clinical data. Federal Register, 1998; 63: 31790-31796.
17. Balant LP, Balant-Gorgia EA,. Cultural differences: implications on drug therapy and global drug development. Int J Clin Pharmacol Ther, 2000; 38: 47-52. (Pubitemid 30077978)
18. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res, 2007; 55: 81-95. (Pubitemid 46186037)
19. Tanaka E,. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther, 1999; 24: 339-346. (Pubitemid 29520783)
20. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Bethesda, MD: US Food and Drug Administration, Center for Drug Evaluation and Research, 2003.
21. SFDA. Guidance for bioavailability and bioequivalence studies for the chemical pharmaceutical preparation. 2005.